Rapid blood test can hasten treatment for stroke patients with brain bleeding
Stroke victims with brain bleeds have nearly seven times higher blood levels of a brain protein called glial fibrillary acidic protein, or GFAP, compared to patients with strokes caused by a blood clot, researchers found.
A blood test that detects GFAP during emergency transport could kick off effective treatment for these patients before they even get to the hospital, potentially reducing their brain damage from stroke, researchers said Thursday ahead of the American Stroke Association's annual meeting in Los Angeles next week.
"It is crucial to differentiate these two types of stroke because they need opposite treatments," lead researcher Dr. Love-Preet Kalra, a neurology resident at the RKH Hospital Klinikum Ludwigsburg in Germany, said in an ASA news release.
"In ischemic stroke, you need to open the blocked blood vessel with clot-busting drugs or physically remove the clot," Kalra added. "In contrast, in a bleeding stroke, you need to lower increased blood pressure and give medication to reverse the effects of certain blood-thinning drugs."
The more time that elapses before a stroke is diagnosed and treated, the more brain tissue is irreparably damaged, researchers said in background notes.
Currently, doctors use imaging scans to distinguish between bleed-based versus clot-caused strokes, researchers said.
Unfortunately, those scans can be delayed for hours while a patient is being stabilized, evaluated in the emergency room and then sent on to radiology, researchers noted. All the while, brain cells are dying.
The research team figured that GFAP might be useful in detecting a brain-bleed stroke. The protein is released into the bloodstream when brain cells are damaged and destroyed, and it's already used when assessing traumatic brain injuries.
The study involved 353 patients treated within six hours of the onset of stroke symptoms.
Blood samples were taken on the way to the emergency room and tested for GFAP levels using a portable blood analyzer.
Brain imaging at the hospital revealed that bleeding strokes had occurred in 76 people, clot-caused strokes in 258 people, and conditions that mimic stroke like seizures or migraine in 19 people.
GFAP levels were nearly seven times higher in bleeding stroke patients compared to those with clot-caused strokes, and more than four times higher in people with a bleeding stroke than a stroke-mimicking condition, results show.
Researchers were able to predict which patients had a bleeding stroke with up to 95% accuracy when age was taken into account, according to their presentation.
In addition, GFAP levels were higher in bleeding stroke patients who were taking blood thinners.
If these results are confirmed in larger studies, the blood test could revolutionize treatment of stroke, Kalra said.
"Treatment to lower blood pressure and reverse blood-thinning medications could be performed in the prehospital setting, leading to a huge change in clinical practice," Kalra said. "In the future, even blood thinners or clot-busting treatment might be applied before people reach the hospital."
American Heart Association volunteer Dr. Louise McCullough agreed that the study results need to be verified in studies involving more people.
"The study had a relatively small sample size, and for the test to be effective, both the patient's blood and the GFAP test must be available as a "point of care" test in the field," McCullough, chief of neurology at Memorial Hermann Hospital-Texas Medical Center in Houston, said in a news release.
"Currently, most ambulances and emergency medical services do not have access to this blood test," McCullough pointed out, who was not involved in the study.
Findings presented at medical meetings should be considered preliminary until published in a peer-reviewed journal.
More information
The U.S. Centers for Disease Control and Prevention has more about stroke.
Copyright © 2025 HealthDay. All rights reserved.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17-07-2025
- Yahoo
UK watchdog bans Trip drinks ad over health, nutrition claims
An advert from UK CBD drinks brand Trip has been banned by the local advertising watchdog over several health and nutrition claims. Last December, Trip promoted a product that did not contain CBD in an online ad. The cucumber and mint beverage came from the company's Mindful Blend range, includes a blend of magnesium, Lion's Mane and other ingredients. Among the claims in the advert was that the drink could "help you feel calm'. The Advertising Standards Authority (ASA) upheld three complaints linked to the advert. The complaints centred on claims the drink reduced stress, promoted feelings of calm and whether a '0g added sugar' nutrition claim breached UK ad rules. The ASA said the advert "implied the magnesium in the product could reduce serum cortisol levels" and included phrases that indicated the product would help consumers relax. It also ruled the claims around the anxiety and stress reducing aspects of Lion's Mane "were claims that a food could prevent, treat or cure disease", which is prohibited by the watchdog's CAP code. "We considered those claims were specific health claims for the purposes of the code, because they implied that the ingredients had beneficial health effects," the ASA said. "However, we had not seen any evidence which demonstrated that those claims were authorised on the GB Register and they therefore breached the Code." Under the code, health claims can only be used in marketing of food and food supplements if they have been authoritised on the GB register. Commenting on the ruling, Rachael Matthews, product director at Trip, said: "All statements regarding the relevant product's calming properties were based on real world studies conducted with human participants. "We will update our advertising and continue to work closely with regulators to ensure that Trip can continue to educate consumers about the functionality of ingredients in its drinks whilst complying with all applicable regulatory requirements.' The third complaint upheld by the ASA was around a claim in the advert that the drink contained "0g added sugar". According to the ASA, such a claim indicates a product is "with no added sugars", though the use of the claim, it said, was allowed "only where a product did not contain any added omo- or disaccharides, or any other food used for its sweetening properties". Given the product contained erythritol and stevia sweeteners, and naturally occuring sugars from fruit concentrate, the ASA ruled the "0g added sugar" claim "did not comply with the conditions of use associated with the equivalent 'with no added sugars' nutrition claim and therefore breached the code". Matthews added: "All sugar used in Trip drinks is naturally occurring from fruit juice. As recognised in the Advertising Standards Authority's ruling, such fruit juice is used for its contribution to a number of different functional aspects of the drinks. "In accordance with the ruling, Trip is taking steps to change its advertising of the relevant product to make this clearer to consumers." "UK watchdog bans Trip drinks ad over health, nutrition claims" was originally created and published by Just Drinks, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Yahoo
16-07-2025
- Yahoo
What is actually in Trip CBD drinks?
The Advertising Standards Authority (ASA) has banned an ad for Trip drinks following unauthorised claims they can "help you feel calm" and reduce stress and anxiety. The self-proclaimed "No. 1 CBD brand" in the UK has since removed this messaging from its marketing material – which included a statement on its website, seen in December, about how the drinks could be used to help people "unwind when work is over" or could be consumed in the morning "before a long day." The brand also claimed that its blend of ingredients – including magnesium citrate – "has been crafted for calm." Following an investigation, which examined complaints over three key issues, the watchdog concluded that the messaging around certain health claims were "not authorised." Yahoo UK has contacted Trip for comment. View this post on Instagram A post shared by TRIP (@ So, what is in Trip? Depending on the flavour, the ingredients vary from drink to drink. However, the base ingredients in all flavours are: Sparkling water Fruit juices from concentrate Flavour enhancers Botanical extracts L-theanine CBD extract Citric acid Sweetener Soya Some blends, such as the raspberry orange blossom and chamomile drink, also include magnesium citrate (according to its site, one 250ml can contains 24mg). Magnesium citrate, specifically, can help relieve constipation by increasing the amount of water your intestines absorb. The mineral magnesium, meanwhile, is important for bodily function and contributes towards healthy nerves, muscles, bones and cardiovascular system. It has also been linked to improved sleep and reduced anxiety. As for the CBD extract present in Trip drinks, the brand states that there is 25mg in each can. The rise of CBD products Cannabidiol (CBD) products have become increasingly popular – not just in the UK, but around the world. According to a 2023 report by the Food Standards Agency (FSA), there were 100 CBD products on its public list, on sale across England and Wales – with more than 12,000 CBD products linked to food applications. Samples included everything from sprays and oils, to beverages and even dog treats. CBD doesn't cause a high, though it is a chemical derived directly from the hemp plant. While there are various health claims associated with the active ingredient, further research is needed to determine its benefits and safety. In conjunction with tetrahydrocannabinol (THC, aka, the psychoactive ingredient in cannabis), it is used in medicine to treat multiple sclerosis (MS) symptoms. Similarly, there are traces of CBD in certain epilepsy medications, too. Read more about health: Are nicotine pouches as bad as vaping and smoking? (Yahoo Life UK, 6-min read) 11 side-effects of cannabis, as Sadiq Khan calls for partial decriminalisation (Yahoo Life UK, 6-min read) Eight foods that have the additive glycerol in, as experts warn against slushies (Yahoo Life UK, 4-min read)
Medscape
16-07-2025
- Medscape
Does Romosozumab Deserve Its Black Box Warning?
Osteoporosis drug romosozumab showed no increased risk for the development of cardiovascular (CV) events compared with anabolic osteoporosis drugs, contrary to its black box warning, new research found. 'These findings suggest there is no heightened risk for major adverse cardiovascular events in patients with osteoporosis treated with romosozumab compared to the anabolic agents teriparatide or abaloparatide,' the authors reported at ENDO 2025: The Endocrine Society Annual Meeting. 'Further observational data is required to concur with such findings, which may lead to a discontinuation of the black box warning,' they said. Romosozumab, a monoclonal antibody targeting sclerostin, has a unique dual action of anabolic properties (increasing bone formation while reducing resorption and improving bone mineral density while reducing vertebral fracture risk). The drug is injected monthly for 12 months, after which time its anabolic effects decline and patients must transition to other antiresorptive therapies, such as bisphosphonates or denosumab, to maintain gains in bone density. Although the FDA approved romosozumab for osteoporosis management, it has given a black box warning after clinical trials (including the ARCH study) comparing romosozumab with alendronate suggested an increased risk for serious CV events, including myocardial infarction, stroke, and CV death. The drug is therefore contraindicated in patients with hypocalcemia and those who have had a myocardial infarction or stroke within the previous year. However, data on those risks has been highly inconsistent, first author Maxim John Levy Barnett, MD, of Jefferson-Einstein Hospital, Philadelphia, told Medscape Medical News . 'Most previous studies on this issue show a nonsignificant trend toward a higher risk but do not reach statistical significance,' he said. Even the ARCH trial 'showed a trend of higher incidence of adverse outcomes, but it was not statistically significant,' he noted. New Findings To further investigate the risks, Barnett and colleagues evaluated data on patients with osteoporosis in the TriNetX database, including 14,760 patients treated with romosozumab and 45,302 treated with either teriparatide or abaloparatide anabolic agents. For the propensity score analysis, patients in the two groups were matched for age, sex, race, glycated hemoglobin, hypertension, chronic kidney disease, ischemic heart disease, cerebrovascular disease, diabetes, and other factors. After matching, the romosozumab group had 14,288 patients compared with 14,362 in the anabolic agent group. Patients had a mean age at baseline of 70.5 years, 94% were women — as the drug is approved in the US for women only — and 71% were White. With a mean follow-up of 5 years (including the 1-year treatment with romosozumab), there was a nonsignificant trend toward a reduced risk for CV incidents among those treated with romosozumab (relative risk [RR], 0.601; P = .0692). The romosozumab group also had significantly lower ischemic heart disease rates than the anabolic agent group (RR, 0.848; P = .0017). In addition, those receiving romosozumab had a lower risk of acute myocardial infarction (RR, 0.654; P < .0001). Likewise, acute heart failure, either systolic or diastolic, was also significantly lower in the romosozumab group (RR, 0.664; P = .0029). 'After propensity-score matching, there was still a significant reduction [with romosozumab], which was a surprise,' Barnett said. 'Three out of the 4 outcomes actually showed a significant decrease in risk with romosozumab.' 'To the best of my knowledge, similar trends have not been noted in other studies,' he said, adding that there have been no significant changes to romosozumab's treatment regimen or other factors that might explain differences in risk since the issuance of the black box warning. 'It is important to note that this was not the primary objective of the noninferiority study, and it was not powered for this endpoint,' Barnett said. The findings nevertheless add to evidence from others showing results that call into question the concerns behind the black box warning. 'There is no substantial evidence for cardiovascular risk and this medication; nonetheless, the black box warning is present,' Barnett said. Commenting on the study, Tiffany Kim, MD, of the University of California, San Francisco, who co-moderated the session, agreed that 'these are definitely interesting findings that add to growing data that romosozumab may not be associated with increased cardiovascular risk.' She noted that, as intended, 'any black box warning has a big effect on how clinicians consider and talk to a patient about the risks of a medication.' 'From a medico-legal perspective, I always inform my patient so they aren't surprised if they read this later, and so that I can document that they accept the benefits outweigh the risk for their individual situation.' 'This study adds to the reassuring literature that romosozumab may not be associated with increased risk of cardiovascular disease,' Kim said. 'In my clinical practice, I only consider anabolic therapy for my patients with severe osteoporosis at high fracture risk who really need treatment, so having more data about the CV risk helps with my clinical decision-making and with discussions with my patients about the risks and benefits of this drug.' In terms of caveats, Kim noted that 'the study did a good job of matching for medical comorbidities, but there may be other factors that cause a clinician to prescribe the drugs that are associated with cardiovascular disease.' 'This study is a helpful addition to the literature, but it's hard to be definitive in an observational study,' she added.
